Thank you for Subscribing to Life Science Review Weekly Brief
A new independent director and chairman of the audit committee has been appointed to Curative Biotechnology Inc.'s Board of Directors.
FREMONT, CA: Curative Biotechnology Inc., a biomedical company in the development stage focused on novel therapies for rare diseases, declares that Marc Drimer, CPA, has joined the company's Board of Directors as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35 years of expertise in the financial services business in all facets of corporate governance, compliance, and operations. He has held senior managerial positions with Hertz Europe and Allied Maintenance in London and Geneva. He earned a BS in Accounting from Brooklyn College and an MBA in Finance from New York University's Graduate School of Business.
Mr. Drimer is currently the Chief Financial Officer of Lampert Capital Markets, Inc., responsible for the firm's financial and operational operations. He is the principal of Financial and Operations and the principal of Options and Municipal Bonds.
He has served as the chief executive officer and chief financial officer of several brokerage firms and investment banks. He was responsible for the origination and syndication of numerous private placements and initial public offerings in various industries. He is licensed in Series 4, 7, 24, 27, 53, 63, and 79.
Chairman and President Paul M. Michaels says, “Adding Marc Drimer to our Board as an independent director is another major milestone for Curative Biotech. Marc has decades of broad experience at the highest levels in the financial services industry and is known for his professionalism and business acumen. We are excited and eager to begin working with Marc in developing capital market options and potential partnerships as the Company advances its therapeutic pipeline.”